In his presentation on optical coherence tomography (OCT) during the 2013 Laser Marketplace Seminar (at Photonics West), Eric Swanson, serial entrepreneur and publisher of OCTnews, provided a comprehensive tour of OCT applications and implementations -- the vast majority of them biomedical. Swanson is a fantastic spokesperson for OCT thanks not only to his pioneering role in its development, but also to his tracking and analysis of its progress. For instance, he outlined the ROI of government support for OCT by discussing the technology's impact on the economy in terms of dollars and jobs, and on patient care (one OCT scan happens every second, he said).
But OCT's overall trajectory continues to climb, and Swanson predicts that gastrointestinal imaging will be its next big success. Yes, he is associated with a company (NinePoint Medical) commercializing this application, but he bases his prediction on analysis of metrics including market needs, technology maturity, and publications to date. Other applications, too, will surely benefit from the size reduction enabled by chip-based OCT (pursued by Tornado Spectral Systems, and others), which promises to dramatically reduce cost as well.
An audience member worried aloud that physicians may be overwhelmed by OCT data they don’t know how to interpret, but Swanson waived off that concern saying that the same concerns existed in ophthalmology and cardiology markets early on.
Swanson pointed out that of the continually increasing number of companies involved in OCT, more than 40% are associated with government-funded research; and he suggested that companies interested in commercializing technology partner with such researchers. Good news for small business: He also noted that 78% of OCT companies are startups.
Showing posts with label OCT. Show all posts
Showing posts with label OCT. Show all posts
Monday, February 4, 2013
Friday, August 10, 2012
OCT systems and application workshop plans growth
Last week I got to spend a little time with attendees at the first annual workshop of the Center for Biomedical OCT Research and Translation (CBORT) in Boston, and by all accounts the event was top shelf. With a focus on optical coherence tomography (OCT) and a mission to pioneer and provide access to microscopic imaging instruments for biologic and clinical research, CBORT was established in 2009 at Massachusetts General Hospital (MGH) and Harvard Medical School, and in 2011 became a National Biomedical Resource Center; the group’s work is highlighted in an article in the July/August 2012 issue of BioOptics World (see OCT for oncology: Preclinical progress highlights clinical potential).
The two-day inaugural workshop, titled OCT: Technical Foundations and Systematic Implementation, brought together a select group of 18 engineers and researchers--from academia and industry around the country and the world--for intense theoretical and practical training of OCT principles and functionality taught by leaders in OCT, including CBORT principal investigator Brett Bouma, Professor of Dermatology and Health Sciences and Technology at Harvard Medical School and Associate Physicist in the Wellman Center for Photomedicine at MGH. The instructors covered light source development, signal processing and system calibration, system integration, imaging probes, and image processing and interpretation.
"Ultimately, it is our mission through these educational programs to further the OCT field and facilitate the widespread acceptance of this technology in research and clinical medicine," said CBORT administrative director Jacqueline Namati, Ph.D. Nemati notes that the workshop will likely expand in the future from a two-day event to "a week-long program with sessions catered to clinicians, engineers, physicists, and biologists."
This is exciting because CBORT--which receives funding from the National Center for Research Resources and the National Institute of Biomedical Imaging and Bioengineering--aims to help advance OCT technology to identify new methods for diagnosis and insights into disease, and formulate new therapeutic strategies or drug targets. A major goal of the center is to cultivate strategic research collaborations and application-specific OCT instrumentation and hardware. All of this activity promises to boost OCT technology even further along the path Eric Swanson describes in his two-part article titled One decade and $500M: The impact of federal funding on OCT. For more information on the center, see CBORT’s website: http://cbort.mgh.harvard.edu/.
The two-day inaugural workshop, titled OCT: Technical Foundations and Systematic Implementation, brought together a select group of 18 engineers and researchers--from academia and industry around the country and the world--for intense theoretical and practical training of OCT principles and functionality taught by leaders in OCT, including CBORT principal investigator Brett Bouma, Professor of Dermatology and Health Sciences and Technology at Harvard Medical School and Associate Physicist in the Wellman Center for Photomedicine at MGH. The instructors covered light source development, signal processing and system calibration, system integration, imaging probes, and image processing and interpretation.
"Ultimately, it is our mission through these educational programs to further the OCT field and facilitate the widespread acceptance of this technology in research and clinical medicine," said CBORT administrative director Jacqueline Namati, Ph.D. Nemati notes that the workshop will likely expand in the future from a two-day event to "a week-long program with sessions catered to clinicians, engineers, physicists, and biologists."
This is exciting because CBORT--which receives funding from the National Center for Research Resources and the National Institute of Biomedical Imaging and Bioengineering--aims to help advance OCT technology to identify new methods for diagnosis and insights into disease, and formulate new therapeutic strategies or drug targets. A major goal of the center is to cultivate strategic research collaborations and application-specific OCT instrumentation and hardware. All of this activity promises to boost OCT technology even further along the path Eric Swanson describes in his two-part article titled One decade and $500M: The impact of federal funding on OCT. For more information on the center, see CBORT’s website: http://cbort.mgh.harvard.edu/.
Monday, May 30, 2011
Biomedical keynotes highlight top growth areas at Laser World of Photonics 2011
Laser World of Photonics 2011 definitely seemed larger than the 2009 event--and the final tally confirmed that indeed it was. The top two growth areas were medical technology and biophotonics, according to Messe Muenchen GmbH; this year’s conference and exhibition attracted not only 8% more visitors (for a total of 27,500) but also a record number of exhibitors (1100).
The event celebrated the 20th anniversary of optical coherence tomography (OCT) with a CLEO Europe and European Conference on Biomedical Optics (ECBO) co-sponsored technology and applications tutorial by OCT pioneer Jim Fujimoto. The MIT professor drew a standing-room-only crowd; so did the two ECBO plenary talks. One, by another OCT powerhouse, Wolfgang Drexler of the Medical University of Wein (Austria), whisked audience members through OCT history highlights, and painted an enthusiastic picture of future technology and market development.
The other ECBO plenary featured Prof. Mary-Ann Mycek of the University of Michigan (USA) discussing an optical spectroscopy technique that offers exciting promise for early detection of pancreatic cancer.
The event celebrated the 20th anniversary of optical coherence tomography (OCT) with a CLEO Europe and European Conference on Biomedical Optics (ECBO) co-sponsored technology and applications tutorial by OCT pioneer Jim Fujimoto. The MIT professor drew a standing-room-only crowd; so did the two ECBO plenary talks. One, by another OCT powerhouse, Wolfgang Drexler of the Medical University of Wein (Austria), whisked audience members through OCT history highlights, and painted an enthusiastic picture of future technology and market development.
The other ECBO plenary featured Prof. Mary-Ann Mycek of the University of Michigan (USA) discussing an optical spectroscopy technique that offers exciting promise for early detection of pancreatic cancer.
Monday, July 20, 2009
OCT for cancer detection/diagnosis
During his appearance last month as the fifth annual Hounsfield memorial lecturer at the Imperial College London (England) Imaging Sciences Centre, MIT professor James Fujimoto said that screening and early stage diagnosis of cancers is a growth area for optical coherence tomography (OCT). Within days of Fujimoto's presentation, a number of announcements from commercial OCT developers addresses the use of the technology for cancer detection.
During his appearance as the fifth annual Hounsfield memorial lecturer at the Imperial College London (England) Imaging Sciences Centre, MIT professor James Fujimoto said that screening and early stage diagnosis of cancers is a growth area for optical coherence tomography (OCT).
Within days of Fujimoto's presentation, Within days of Fujimoto's presentation, OCT developer Volcano (San Diego, CA) told Massachusetts business journal Mass High Tech that it hopes to branch into cancer diagnosis--and another announcement reported a novel cancer detection system based on optical demultiplexed (OD) optical coherence tomography (OCT).
Similarly, skin cancer detection is a potential application of Michelson Diagnostics' VivoSight system, just released for clinical use in Europe.
During his appearance as the fifth annual Hounsfield memorial lecturer at the Imperial College London (England) Imaging Sciences Centre, MIT professor James Fujimoto said that screening and early stage diagnosis of cancers is a growth area for optical coherence tomography (OCT).
Within days of Fujimoto's presentation, Within days of Fujimoto's presentation, OCT developer Volcano (San Diego, CA) told Massachusetts business journal Mass High Tech that it hopes to branch into cancer diagnosis--and another announcement reported a novel cancer detection system based on optical demultiplexed (OD) optical coherence tomography (OCT).
Similarly, skin cancer detection is a potential application of Michelson Diagnostics' VivoSight system, just released for clinical use in Europe.
Monday, April 20, 2009
Cardiac imaging and OCT's legal mess
"Word is getting out” about imaging tools that enable more precise guidance during heart surgery, said Volcano Corp. VP Joe Burnett, referring to the increased number of imaging-related presentations at the recent American College of Cardiology (ACC) Annual Meeting 2009.) Speaking at the conference, former ACC President Pamela Douglas, M.D. said that imaging is growing faster than all other procedures, services and diagnostic tests.
Many of the talks focused on intravascular ultrasound (IVUS) and optical coherence tomography (OCT), either pitting the approaches against each other or demonstrating their complementary use. Volcano has a foot in each camp, bolstered during the past year by acquisitions of IVUS developer Novelis and OCT developer Axsun. The latter launched a legal battle because last summer, Axsun entered into a multi-year exclusive agreement with another supplier of cardiac OCT systems, LightLab Imaging (Westford, MA). Under the agreement, Axsun would supply advanced tunable lasers for LightLab’s swept-source OCT systems.
We’re still waiting for the final answer to the question, “What happens when the company you acquire has supply agreements with your competitors?” but for now, a Superior Court injunction, in response to a complaint by LightLab, is prohibiting Volcano from using Axsun tunable lasers in its OCT products.
Many of the talks focused on intravascular ultrasound (IVUS) and optical coherence tomography (OCT), either pitting the approaches against each other or demonstrating their complementary use. Volcano has a foot in each camp, bolstered during the past year by acquisitions of IVUS developer Novelis and OCT developer Axsun. The latter launched a legal battle because last summer, Axsun entered into a multi-year exclusive agreement with another supplier of cardiac OCT systems, LightLab Imaging (Westford, MA). Under the agreement, Axsun would supply advanced tunable lasers for LightLab’s swept-source OCT systems.
We’re still waiting for the final answer to the question, “What happens when the company you acquire has supply agreements with your competitors?” but for now, a Superior Court injunction, in response to a complaint by LightLab, is prohibiting Volcano from using Axsun tunable lasers in its OCT products.
Wednesday, January 7, 2009
It's bad, but not all bad
Yes, it's bad out there. But it's not all bad.
Laser vision correction doesn't yet show signs of recovery; the eye-surgery market research firm Market Scope predicts the segment will finish 2008 with a 17% drop. And the aesthetics sector is similarly struggling: Candela reported revenues down 24.2% in its first fiscal quarter from $35.5 million in the comparable prior-year period; Cutera’s Q3 2008 results were well below management's guidance and the consensus estimates, and Syneron reported revenues for Q3 2008 of $28.5 million, down from $33.1 million in Q3 2007 (even though the company’s international sales rose 17% year over year).
Yes, it's bad out there. But it's not all bad.
Laser vision correction doesn't yet show signs of recovery; the eye-surgery market research firm Market Scope predicts the segment will finish 2008 with a 17% drop. And the aesthetics sector is similarly struggling: Candela reported revenues down 24.2% in its first fiscal quarter from $35.5 million in the comparable prior-year period; Cutera’s Q3 2008 results were well below management's guidance and the consensus estimates, and Syneron reported revenues for Q3 2008 of $28.5 million, down from $33.1 million in Q3 2007 (even though the company’s international sales rose 17% year over year).
But on the up side, aesthetic laser company Cynosure bucked the trend with 21% growth in Q3 revenues. More good news: Strategic Directions International notes that handheld and portable molecular spectroscopy should see “very strong growth for the foreseeable future." This week, cardiovascular OCT systems developer LightLab discussed a similarly positive outlook, while AngioDynamics, Inc., which this summer acquired Diomed, reported net sales for its fiscal second quarter were up 17% over the $41.5 million reported in Q2 a year ago.
The January issue of Laser Focus World quotes Phil Crowley of MarketTech, a laser distribution, sales, and service company, as saying, “With a vast majority of our laser business in biotech, we haven’t seen a slowdown yet.” He said he is “encouraged that higher power levels, broader wavelength range offerings, smaller packages, and price reductions can result in further penetration of lasers into many biomedical instruments for DNA sequencing and disease analysis, flow cytometry, and microscopy.”
Laser vision correction doesn't yet show signs of recovery; the eye-surgery market research firm Market Scope predicts the segment will finish 2008 with a 17% drop. And the aesthetics sector is similarly struggling: Candela reported revenues down 24.2% in its first fiscal quarter from $35.5 million in the comparable prior-year period; Cutera’s Q3 2008 results were well below management's guidance and the consensus estimates, and Syneron reported revenues for Q3 2008 of $28.5 million, down from $33.1 million in Q3 2007 (even though the company’s international sales rose 17% year over year).
Yes, it's bad out there. But it's not all bad.
Laser vision correction doesn't yet show signs of recovery; the eye-surgery market research firm Market Scope predicts the segment will finish 2008 with a 17% drop. And the aesthetics sector is similarly struggling: Candela reported revenues down 24.2% in its first fiscal quarter from $35.5 million in the comparable prior-year period; Cutera’s Q3 2008 results were well below management's guidance and the consensus estimates, and Syneron reported revenues for Q3 2008 of $28.5 million, down from $33.1 million in Q3 2007 (even though the company’s international sales rose 17% year over year).
But on the up side, aesthetic laser company Cynosure bucked the trend with 21% growth in Q3 revenues. More good news: Strategic Directions International notes that handheld and portable molecular spectroscopy should see “very strong growth for the foreseeable future." This week, cardiovascular OCT systems developer LightLab discussed a similarly positive outlook, while AngioDynamics, Inc., which this summer acquired Diomed, reported net sales for its fiscal second quarter were up 17% over the $41.5 million reported in Q2 a year ago.
The January issue of Laser Focus World quotes Phil Crowley of MarketTech, a laser distribution, sales, and service company, as saying, “With a vast majority of our laser business in biotech, we haven’t seen a slowdown yet.” He said he is “encouraged that higher power levels, broader wavelength range offerings, smaller packages, and price reductions can result in further penetration of lasers into many biomedical instruments for DNA sequencing and disease analysis, flow cytometry, and microscopy.”
Friday, November 21, 2008
OCT at AAO: faster, broader
At the American Academy of Ophthalmology (AAO) annual meeting 2008, which concluded last week in Atlanta, optical coherence tomography (OCT) was well represented both in the conference program (with several sessions dedicated to the topic and several more touching on it) and in the exhibit hall. Bioptigen, Carl Zeiss Meditec, Heidelberg, OPKO, Optopol, Optovue, and Topcon all exhibited -- most with large booths. Canon joined the OCT crowd too, demonstrating the use of its technology with Optopol's OCT system, so Optopol got double the exposure with Canon’s exhibit. Nidek wasn’t talking about its rumored OCT offering, but I’m guessing that company will release a system within a year. Of course the exhibitors emphasized eye care, but there was talk among some of OCT for other disciplines, including non-biomedical applications such as manufacturing.
At the American Academy of Ophthalmology (AAO) annual meeting 2008, which concluded last week in Atlanta, optical coherence tomography (OCT) was well represented both in the conference program (with several sessions dedicated to the topic and several more touching on it) and in the exhibit hall. Bioptigen, Carl Zeiss Meditec, Heidelberg, OPKO, Optopol, Optovue, and Topcon all exhibited -- most with large booths. Canon joined the OCT crowd too, demonstrating the use of its technology with Optopol's OCT system, so Optopol got double the exposure with Canon’s exhibit. Nidek wasn’t talking about its rumored OCT offering, but I’m guessing that company will release a system within a year. Of course the exhibitors emphasized eye care, but there was talk among some of OCT for other disciplines, including non-biomedical applications such as manufacturing.
A 2-1/2 hour OCT session that required additional payment drew an audience of more than 200. When the moderator asked how many attendees currently have OCT systems, most raised their hands—and about 25% indicated they own spectral domain (Fourier domain) OCT systems. Not surprisingly, most of the attendees are focused on retinal applications, but about 15% or so use OCT for corneal work.
An overview of OCT emphasized the speed difference between the older time domain systems and the new breed of spectral/Fourier domain units -- but it was noted that the real bottleneck these days for OCT is computer processing time. That’s why last week’s announcement by Texas Instruments is so exciting; TI’s new embedded processors specifically target medical imaging.
At the American Academy of Ophthalmology (AAO) annual meeting 2008, which concluded last week in Atlanta, optical coherence tomography (OCT) was well represented both in the conference program (with several sessions dedicated to the topic and several more touching on it) and in the exhibit hall. Bioptigen, Carl Zeiss Meditec, Heidelberg, OPKO, Optopol, Optovue, and Topcon all exhibited -- most with large booths. Canon joined the OCT crowd too, demonstrating the use of its technology with Optopol's OCT system, so Optopol got double the exposure with Canon’s exhibit. Nidek wasn’t talking about its rumored OCT offering, but I’m guessing that company will release a system within a year. Of course the exhibitors emphasized eye care, but there was talk among some of OCT for other disciplines, including non-biomedical applications such as manufacturing.
A 2-1/2 hour OCT session that required additional payment drew an audience of more than 200. When the moderator asked how many attendees currently have OCT systems, most raised their hands—and about 25% indicated they own spectral domain (Fourier domain) OCT systems. Not surprisingly, most of the attendees are focused on retinal applications, but about 15% or so use OCT for corneal work.
An overview of OCT emphasized the speed difference between the older time domain systems and the new breed of spectral/Fourier domain units -- but it was noted that the real bottleneck these days for OCT is computer processing time. That’s why last week’s announcement by Texas Instruments is so exciting; TI’s new embedded processors specifically target medical imaging.
Thursday, October 30, 2008
Big names in bio at FiO
I knew I’d find some interesting things at the OSA’s Frontiers in Optics event last week, but I actually found much more than I expected. Two of the conference tracks were mainly dedicated to bio topics, and beyond that, several other presentations also also focused on bio. For instance, James Fujimoto of MIT, widely recognized for his invention and application of optical coherence tomography (OCT), presented on the use of OCT for biomedical applications as part of a tribute to Dr. Howard Schlossberg of the Air Force Office of Scientific Research.
I knew I’d find some interesting things at the OSA’s Frontiers in Optics event last week, but I actually found much more than I expected. Two of the conference tracks were mainly dedicated to bio topics, and beyond that, several other presentations also also focused on bio. For instance, renowned scientist James Fujimoto of MIT, widely recognized for his invention and application of optical coherence tomography (OCT), presented on the use of OCT for biomedical applications as part of a tribute to Dr. Howard Schlossberg of the Air Force Office of Scientific Research.
Among other “big names” in biomedical optics attending the event was OSA president-elect Dr. Tom Baer, who is Executive Director of the Stanford Photonics Research Center at Stanford University and co-founder of Arcturus Bioscience, Inc. And also Dr. Robert R. Alfano, Distinguished Professor of Science and Engineering at City University of New York, and director of the Institute for Ultrafast Spectroscopy and Lasers. At the time, Prof. Alfano was preparing the webcast that he presented yesterday along with Dr. Stavros Demos of Lawrence Livermore National Lab and UC Davis, called Key secrets of biospectroscopy. We’ve gotten very positive response on the webcast, by the way, so check it out if you’ve got an interest in the spectroscopy for cancer detection and other life sciences work. (Just click the “register” button and you’ll be able to view or download the whole presentation or just an MP3 audio file.)
Prof. Alfano shared with me some great stories of his career, which I’ll highlight in the November/December issue. (Did you know that his discovery of the ultrafast supercontinuum light source was an accident?)
More information:
"Key secrets of biospectroscopy" webcast
OSA’s Frontiers in Optics 2008
Dr. Howard Schlossberg bio
I knew I’d find some interesting things at the OSA’s Frontiers in Optics event last week, but I actually found much more than I expected. Two of the conference tracks were mainly dedicated to bio topics, and beyond that, several other presentations also also focused on bio. For instance, renowned scientist James Fujimoto of MIT, widely recognized for his invention and application of optical coherence tomography (OCT), presented on the use of OCT for biomedical applications as part of a tribute to Dr. Howard Schlossberg of the Air Force Office of Scientific Research.
Among other “big names” in biomedical optics attending the event was OSA president-elect Dr. Tom Baer, who is Executive Director of the Stanford Photonics Research Center at Stanford University and co-founder of Arcturus Bioscience, Inc. And also Dr. Robert R. Alfano, Distinguished Professor of Science and Engineering at City University of New York, and director of the Institute for Ultrafast Spectroscopy and Lasers. At the time, Prof. Alfano was preparing the webcast that he presented yesterday along with Dr. Stavros Demos of Lawrence Livermore National Lab and UC Davis, called Key secrets of biospectroscopy. We’ve gotten very positive response on the webcast, by the way, so check it out if you’ve got an interest in the spectroscopy for cancer detection and other life sciences work. (Just click the “register” button and you’ll be able to view or download the whole presentation or just an MP3 audio file.)
Prof. Alfano shared with me some great stories of his career, which I’ll highlight in the November/December issue. (Did you know that his discovery of the ultrafast supercontinuum light source was an accident?)
More information:
"Key secrets of biospectroscopy" webcast
OSA’s Frontiers in Optics 2008
Dr. Howard Schlossberg bio
Subscribe to:
Posts (Atom)